Parallel Advisors LLC Increases Position in Thermo Fisher Scientific Inc. $TMO

Parallel Advisors LLC boosted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 3.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,051 shares of the medical research company’s stock after acquiring an additional 1,157 shares during the quarter. Parallel Advisors LLC’s holdings in Thermo Fisher Scientific were worth $18,212,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Planning Alternatives Ltd. ADV increased its position in shares of Thermo Fisher Scientific by 26.0% during the 1st quarter. Planning Alternatives Ltd. ADV now owns 752 shares of the medical research company’s stock valued at $370,000 after purchasing an additional 155 shares during the last quarter. SEB Asset Management AB purchased a new stake in Thermo Fisher Scientific in the first quarter worth approximately $93,523,000. Swiss National Bank grew its position in Thermo Fisher Scientific by 6.6% during the first quarter. Swiss National Bank now owns 1,102,640 shares of the medical research company’s stock valued at $541,981,000 after acquiring an additional 67,840 shares during the last quarter. Legacy Wealth Advisors LLC raised its stake in shares of Thermo Fisher Scientific by 151.4% during the first quarter. Legacy Wealth Advisors LLC now owns 1,023 shares of the medical research company’s stock worth $503,000 after acquiring an additional 616 shares in the last quarter. Finally, Spartan Wealth Advisory Services LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter worth approximately $4,010,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Down 0.1%

NYSE TMO opened at $532.17 on Monday. The stock has a market cap of $197.77 billion, a P/E ratio of 29.26, a price-to-earnings-growth ratio of 2.36 and a beta of 0.87. Thermo Fisher Scientific Inc. has a fifty-two week low of $403.36 and a fifty-two week high of $643.99. The stock has a 50 day simple moving average of $484.57 and a two-hundred day simple moving average of $514.39. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.15 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period in the previous year, the firm earned $5.15 earnings per share. The business’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 24.84 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio is 10.34%.

Insider Activity at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 0.33% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on TMO. Piper Sandler assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, June 11th. They set a “neutral” rating and a $510.00 target price on the stock. Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research report on Friday, May 8th. Stifel Nicolaus decreased their price objective on Thermo Fisher Scientific from $700.00 to $600.00 and set a “buy” rating on the stock in a report on Friday, April 24th. Sanford C. Bernstein began coverage on Thermo Fisher Scientific in a research note on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price for the company. Finally, KeyCorp restated an “overweight” rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $602.14.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.